You will be shown an abstract from a biomedical research paper. Given this abstract, your task is to extract all unique entities of the following types: ["Outcome", "Participant", "Intervention"].

Please return the output as a JSON object of the format: {"Participant" : ["patients with COPD", ...], "Intervention" : ["Atenolol", ...], "Outcome" : ["blood pressure", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

Comparison of meloxicam and a glucosamine-chondroitin supplement in management of feline osteoarthritis . A double-blind randomised , placebo-controlled , prospective trial . OBJECTIVE To compare the efficacy of meloxicam and a glucosamine-chondroitin ( Glu-Ch ) supplement in the management of feline osteoarthritis ( OA ) . METHODS Prospective , blinded , randomized clinical trial . Cats over eight years of age with clinical signs of chronic OA were assigned to one of two groups and Glu-Ch or meloxicam was administered orally for 70 days , followed by a placebo until day 98 . Cats were assessed by a veterinarian on five occasions and the owner completed an assessment form at the same time . RESULTS Data were collected from thirty cats . Pre-treatment disease scores were significantly higher in the meloxicam group for owner mobility ( p=0.01 ) and veterinary lameness ( p=0.02 ) . Owner mobility scores at day 14 ( p=0.01 ) and day 42 ( p=0.002 ) were significantly improved compared to pre-treatment scores for the meloxicam group . When meloxicam and Glu-Ch were discontinued and the placebo commenced , a significant proportion of the meloxicam group showed worsening of all the owner-assessed scores between day 70 and day 98 , when compared to the Glu-Ch group ( mobility p=0.01 ; activity p=0.02 ; temperament p=0.04 ; lifestyle p=0.01 ) . CONCLUSIONS Treatment with meloxicam resulted in a significant improvement in mobility and activity levels of cats with OA until the placebo was introduced . A greater proportion of cats receiving meloxicam medication showed a significant worsening of owner assessment scores once the placed was introduced , when compared to the Glu-Ch group .
{"Intervention": ["placebo", "meloxicam", "glucosamine-chondroitin ( Glu-Ch ) supplement", "glucosamine-chondroitin supplement", "Glu-Ch or meloxicam"], "Outcome": ["activity levels", "Owner mobility scores", "feline osteoarthritis .", "owner mobility", "feline osteoarthritis ( OA )", "veterinary lameness", "mobility"], "Participant": ["clinical signs of chronic OA", "Cats over eight years of age", "feline osteoarthritis", "feline osteoarthritis ( OA )"]}